Clearing the air: Uniquely engaging furin as an approach to cystic fibrosis therapy

Digant Nayak; Elizabeth V. Wasmuth; Shaun K. Olsen

doi:10.1016/j.chembiol.2022.05.011

Clearing the air: Uniquely engaging furin as an approach to cystic fibrosis therapy

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In this issue of Cell Chemical Biology, Douglas et al. describe a potent, specific, and cell-permeable furin inhibitor that interacts with a cryptic binding site to rescue hallmarks of cystic fibrosis in human ex vivo models. BOS-318 holds promise for development of therapeutics targeting an array of furin-dependent pathologies.

Original language	English (US)
Pages (from-to)	927-929
Number of pages	3
Journal	Cell Chemical Biology
Volume	29
Issue number	6
DOIs	https://doi.org/10.1016/j.chembiol.2022.05.011
State	Published - Jun 16 2022

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.1016/j.chembiol.2022.05.011

Cite this

@article{bf6b3d6581a24cc6bef8e873d2fd88a5,

title = "Clearing the air: Uniquely engaging furin as an approach to cystic fibrosis therapy",

abstract = "In this issue of Cell Chemical Biology, Douglas et al. describe a potent, specific, and cell-permeable furin inhibitor that interacts with a cryptic binding site to rescue hallmarks of cystic fibrosis in human ex vivo models. BOS-318 holds promise for development of therapeutics targeting an array of furin-dependent pathologies.",

author = "Digant Nayak and Wasmuth, \{Elizabeth V.\} and Olsen, \{Shaun K.\}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = jun,

day = "16",

doi = "10.1016/j.chembiol.2022.05.011",

language = "English (US)",

volume = "29",

pages = "927--929",

journal = "Cell Chemical Biology",

issn = "2451-9456",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Clearing the air

T2 - Uniquely engaging furin as an approach to cystic fibrosis therapy

AU - Nayak, Digant

AU - Wasmuth, Elizabeth V.

AU - Olsen, Shaun K.

PY - 2022/6/16

Y1 - 2022/6/16

N2 - In this issue of Cell Chemical Biology, Douglas et al. describe a potent, specific, and cell-permeable furin inhibitor that interacts with a cryptic binding site to rescue hallmarks of cystic fibrosis in human ex vivo models. BOS-318 holds promise for development of therapeutics targeting an array of furin-dependent pathologies.

AB - In this issue of Cell Chemical Biology, Douglas et al. describe a potent, specific, and cell-permeable furin inhibitor that interacts with a cryptic binding site to rescue hallmarks of cystic fibrosis in human ex vivo models. BOS-318 holds promise for development of therapeutics targeting an array of furin-dependent pathologies.

UR - https://www.scopus.com/pages/publications/85132454254

UR - https://www.scopus.com/pages/publications/85132454254#tab=citedBy

U2 - 10.1016/j.chembiol.2022.05.011

DO - 10.1016/j.chembiol.2022.05.011

M3 - Comment/debate

C2 - 35714591

AN - SCOPUS:85132454254

SN - 2451-9456

VL - 29

SP - 927

EP - 929

JO - Cell Chemical Biology

JF - Cell Chemical Biology

IS - 6

ER -

Clearing the air: Uniquely engaging furin as an approach to cystic fibrosis therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this